Last checked at 1 Jul 2022 07:00
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Allergy Therapeutics showcases allergy immunotherapy leadership at Congress of the European Academy of Allergy and Clinical Immunology (EAACI) 2022
1 July 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces that the Group will be sharing key scientific findings from across its research portfolio at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, taking place from today until 3 July 2022.
The EAACI Congress is the world's largest scientific conference specialising in the field of allergy and clinical immunology and the flagship meeting of the European Academy of Allergy and Clinical Immunology, an association of more than 12,000 clinicians, researchers, and allied health professionals, dedicated to improving the health of people affected by allergic diseases.
Among its 18 posters being presented, Allergy Therapeutics will share:
· Further data from preclinical studies demonstrating the potential of the Group's novel virus-like particle (VLP) based peanut allergy vaccine candidate ("VLP Peanut") which will enter Phase I clinical evaluation later this year
· Detailed findings from the positive G309 exploratory field study which evaluated the efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. These findings supported the design of G306, Allergy Therapeutics' pivotal Phase III trial, which is on track for commencement later this year
· Preclinical and clinical studies examining the effect on pollen and dust mite allergies of immunoBON, the Group's novel targeted micro-nutrition FSMP (Food for Special Medical Purpose) which is based on the so-called "protective farm effect"
Allergy Therapeutics will also be hosting two symposia during the congress:
· A hybrid symposium, "Advancing Allergen Immunotherapy", taking place today, Friday 1 July 2022, 13:15 - 14:45 CET, and chaired by Professor Erika Jensen-Jarolim, MD, Clinical Immunologist, Division of Comparative Medicine, Messerli Research Institute, Medical University of Vienna, will consist of three presentations covering the optimisation of allergy immunotherapy study design, innovative approaches to allergy field trials and the potential of biomarker strategies in allergy immunotherapy trials.
· A digital mini symposium, "MicroCrystalline Tyrosine-associated allergoids: Reaching the top of the evidence pyramid", taking place on Saturday 2 July 2022, 10:30 - 11:00 CET, presented by Professor Ralph Mösges, Fellow of the American Academy of Allergy Asthma and Immunology, Otorhinolaryngologist, Allergologist, University Hospital Cologne, Germany.
Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, commented: "Allergy Therapeutics is committed to developing novel, short-course allergy immunotherapies to transform patients' lives. With a strong presence at this year's EAACI congress, where we are presenting 18 posters and hosting two symposia, we are demonstrating the strength of our science and our commitment to continued innovation. Our latest findings pave the way for the initiation of two key clinical trials later this year - a Phase III trial of our short-course grass pollen immunotherapy candidate, Grass MATA MPL, and the Phase I PROTECT trial of our peanut allergy vaccine candidate, VLP Peanut."
The complete list of Allergy Therapeutics-sponsored abstracts accepted by EAACI for presentation are available on the Group's website.
No new material price sensitive information is expected to be disclosed on Allergy Therapeutics at the EAACI Congress 2022.
Allergy Therapeutics' Hybrid Symposium Advancing Allergen Immunotherapy Friday 1 July 2022; 13:15 - 14:45 (CET) | |
Introduction Chair: Prof. Erika Jensen-Jarolim, MD, Clinical Immunologist, Division of Comparative Medicine, Messerli Research Institute, Medical University of Vienna, Austria | Symposium Overview & Introductions |
Speaker Prof. Ludger Klimek, Head of the Center for Rhinology and Allergology, Wiesbaden, Germany | Optimisation of study design: What did we learn during the last decade? |
Speaker: Prof. Stefan Zielen, Director and Senior Consultant at Frankfurt University Hospital in the Department of Paediatrics, Germany | Ground-breaking results of an exploratory AIT field trial: innovative approaches to succeed |
Speaker: Prof. Mohamed Shamji, Reader in Immunology & Allergy at Imperial College London, United Kingdom | Shaping the future of AIT trials based on novel biomarker strategies |
Chair: Dr. Ignacio Dávila, Assistant Professor of Allergy at University of Salamanca, Spain | Q&A |
Digital Company Sponsored Mini Symposium MicroCrystalline Tyrosine-associated allergoids: Reaching the top of the evidence pyramid Saturday 2nd July 2022; 10:30 - 11:00 (CET) | |
Prof. Ralph Mösges, Fellow of the American Academy of Allergy Asthma and Immunology, Otorhinolaryngologist, Allergologist, University Hospital Cologne, Germany | MicroCrystalline Tyrosine-associated allergoids: Reaching the top of the evidence pyramid |
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon (Nominated Adviser and Broker)
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.